Lp(a) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD), and elevated levels are associated with increased risk of coronary heart disease (CHD), ischaemic stroke, peripheral artery disease (PAD), heart failure, aortic valve stenosis (AVS), and mitral valve stenosis.1,2
Educational Partners and Supporters
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
(Founding Partner)